VXRT Vaxart

Vaxart to Present Research on Second-Generation Norovirus Oral Pill Vaccine Candidate at IDWeek 2025

Vaxart to Present Research on Second-Generation Norovirus Oral Pill Vaccine Candidate at IDWeek 2025

SOUTH SAN FRANCISCO, Calif., Oct. 20, 2025 (GLOBE NEWSWIRE) -- Vaxart, Inc. (OTCQX: VXRT) (“Vaxart”), a clinical-stage biotechnology company developing a range of oral recombinant pill vaccines based on its proprietary delivery platform, today announced that it will present research featuring its second-generation norovirus oral pill vaccine candidate at IDWeek 2025 taking place October 19-22, 2025, at the Georgia World Congress Center in Atlanta.

IDWeek Oral Abstract Presentation: 

Presentation Title: An Open-Label Phase 1 Clinical Trial Demonstrating Improved Immune Responses to Norovirus Strains GI.1 and GII.4 from a Next Generation Oral Bivalent Vaccine Candidate

Session Title: Late Breaking Trial Results For Viral and Bacterial Infections

Presenter: Nicholas J. Bennett MBBChir, PhD, Vaxart Medical Director

Session Date and Time: Monday, October 20, 2025, 1:45 PM - 3:00 PM ET

Location: B401-B402

About Vaxart 

Vaxart is a clinical-stage biotechnology company developing a range of oral recombinant vaccines based on its proprietary delivery platform. Vaxart vaccines are designed to be administered using pills that can be stored and shipped without refrigeration and eliminate the risk of needle-stick injury. Vaxart believes that its proprietary pill vaccine delivery platform is suitable to deliver recombinant vaccines, positioning the company to develop oral versions of currently marketed vaccines and to design recombinant vaccines for new indications. Vaxart’s development programs currently include pill vaccines designed to protect against coronavirus, norovirus and influenza, as well as a therapeutic vaccine for human papillomavirus (HPV), Vaxart’s first immune-oncology indication. Vaxart has filed broad domestic and international patent applications covering its proprietary technology and creations for oral vaccination using adenovirus and TLR3 agonists.

Contact

Vaxart Media and Investor Relations        

Matt Steinberg

FINN Partners



(646) 871-8481

This press release was published by a CLEAR® Verified individual.



EN
20/10/2025

Underlying

VXRTVaxart

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Vaxart

 PRESS RELEASE
Free
VXRT VAXART

Vaxart Provides Business Update and Reports Third Quarter 2025 Financi...

Vaxart Provides Business Update and Reports Third Quarter 2025 Financial Results Entered into an exclusive license agreement with Dynavax for the Company’s COVID-19 oral pill vaccine candidate for potential cumulative proceeds of up to $700 million plus royalties Completed enrollment of approximately 5,400 participants in COVID-19 Phase 2b trial with topline data expected in late 2026; Topline data from 400-person sentinel cohort anticipated in the first quarter of 2026 Reported additional supportive data from Phase 1 clinical trial evaluating Company’s second-generation oral norovirus va...

9h / 13m 1 EN
 PRESS RELEASE
Free
VXRT VAXART

Vaxart to Host Upcoming Conference Calls

Vaxart to Host Upcoming Conference Calls Third quarter 2025 results conference call to be held on November 13 at 4:30 p.m. ET Stockholder fireside chat to be held on November 18 at 4:30 p.m. ET SOUTH SAN FRANCISCO, Calif., Nov. 07, 2025 (GLOBE NEWSWIRE) -- Vaxart, Inc. (OTCQX: VXRT) (“Vaxart”) today announced it will host two upcoming webcast conference calls. Third Quarter 2025 Financial ResultsVaxart will provide a business update and report financial results for the third quarter ended September 30, 2025, after the market close on Thursday, November 13, 2025. The Vaxart senior mana...

November 7, 2025 1 EN
 PRESS RELEASE
Free
VXRT VAXART

Vaxart to Present Research on Second-Generation Norovirus Oral Pill Va...

Vaxart to Present Research on Second-Generation Norovirus Oral Pill Vaccine Candidate at IDWeek 2025 SOUTH SAN FRANCISCO, Calif., Oct. 20, 2025 (GLOBE NEWSWIRE) -- Vaxart, Inc. (OTCQX: VXRT) (“Vaxart”), a clinical-stage biotechnology company developing a range of oral recombinant pill vaccines based on its proprietary delivery platform, today announced that it will present research featuring its second-generation norovirus oral pill vaccine candidate at IDWeek 2025 taking place October 19-22, 2025, at the Georgia World Congress Center in Atlanta. IDWeek Oral Abstract Presentation: Presen...

October 20, 2025 1 EN
 PRESS RELEASE
Free
VXRT VAXART

Vaxart to Showcase its Norovirus and COVID-19 Oral Pill Vaccine Candid...

Vaxart to Showcase its Norovirus and COVID-19 Oral Pill Vaccine Candidates at World Vaccine Congress Europe 2025 SOUTH SAN FRANCISCO, Calif., Oct. 08, 2025 (GLOBE NEWSWIRE) -- Vaxart, Inc. (OTCQX: VXRT) (“Vaxart” or the “Company”), a clinical-stage biotechnology company developing a range of oral recombinant pill vaccines based on its proprietary delivery platform, today announced that it will present research highlighting its advances in its norovirus and COVID-19 programs at the World Vaccine Congress Europe 2025 taking place in Amsterdam on October 13-16, 2025. Vaxart’s mission is to ...

October 8, 2025 1 EN
 PRESS RELEASE
Free
VXRT VAXART

Vaxart Announces Withdrawal of Reverse Stock Split Proposal

Vaxart Announces Withdrawal of Reverse Stock Split Proposal SOUTH SAN FRANCISCO, Calif., Sept. 19, 2025 (GLOBE NEWSWIRE) -- Vaxart, Inc. (OTCQX: VXRT) (“Vaxart” or the “Company”), a clinical-stage biotechnology company developing a range of oral recombinant pill vaccines based on its proprietary delivery platform, announced that it has withdrawn its reverse stock split proposal. “After careful consideration, we have decided to officially withdraw our reverse stock split proposal. Moving forward, we will continue to communicate frequently with our stockholders across multiple channels...

September 19, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch